Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
Phase 2
60
about 4.8 years
6–35
2 sites in CO, FL
About this study
This trial is testing a new way to treat type 1 diabetes. It involves using anti-thymocyte globulin (ATG) with or without verapamil, and it aims to improve how well the treatment works for each person. The goal is to find better ways to manage type 1 diabetes by understanding what makes people respond differently to the treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Anti-thymocyte globulin (ATG)
- 2.Take Placebo
- 3.Take verapamil extended release capsule
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
verapamil (Calcium channel blocker; slows heart rate and dilates vessels)
oral
Primary: AUC C-peptide between ATG and placebo values, Change in 2-hr MMTT AUC C-peptide
Endocrinology